Tag: Ultragenyx

A total of 11 posts are filed under Ultragenyx
FDA Grants Priority Review Status to Ultragenyx
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and… Continue Reading
Takeda to Invest $65M in Ultragenyx under Rare Disease Drug Collaboration
SOURCE Ultragenyx Pharmaceutical will license and co-develop at least one and possibly up to six candidates from Takeda Pharmaceutical,… Continue Reading
Global Genes’ Barbara Lavery Attends XLH Network Day
By Barbara Lavery On Friday and Saturday of this week, I participated in the West Coast XLH Network Day on behalf of Global Genes. The… Continue Reading
Ultragenyx Granted Orphan Drug Designation for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and… Continue Reading
Startup Ultragenyx Snags PiII Program for Growing Rare-Disease Pipeline
Flush from raising more than $100 million, Novato, CA-based startup Ultragenyx Pharmaceutical has stepped up with a new pact to partner on… Continue Reading
A RARE DISEASE PATIENT PERSPECTIVE – Roy Zeighami
A Rare Disease Patient Perspective I would like to use this blog post to explain why the rare disease community is different, and why it… Continue Reading
‘R.A.R.E.’ BOARD OF DIRECTORS AND ADVISORS ANNOUNCED
The RARE Project Announces Big Team Additions, Setting the Stage For Continued Success Thirty (30) million people in the US and 350 million… Continue Reading